Journal of Clinical Endocrinology & Metabolism, Vol 79, 415-420, Copyright © 1994 by Endocrine Society

ARTICLES

Adult height in girls with idiopathic true precocious puberty

R Brauner, L Adan, F Malandry and D Zantleifer
Pediatric Endocrinology Unit, Hopital et Faculte Necker-Enfants Malades, Paris, France.

GnRH analogs are used to suppress pituitary-gonadal activity in children with true precocious puberty. The indications for therapy in this situation are not established, as some girls have a slow evolutive form, and the capacity of GnRH analogs to preserve the adult height has not been evaluated. This study analyzes the growth and adult heights of 2 groups of girls with idiopathic true precocious puberty, 1 with a predicted height of 155 cm or less (group 1, 19 cases) and the other with a predicted height of more than 155 cm (group 2, 15 cases). Group 1 patients were treated with a long-acting GnRH analog (D-Trp6-GnRH), and group 2 patients were followed without therapy. Group 1 showed greater clinical signs of estrogenization, vaginal maturation index (P < 0.03), plasma estradiol (P < 0.0004), and ratio of LH/FSH peaks (P < 0.01) at the initial evaluation than did group 2. The mean target heights were similar (difference, 0.9 cm). In group 1, the adult height (159 +/- 1.1 cm) was greater than the predicted height before therapy (152 +/- 1.4 cm; P < 0.0001). The difference between the adult height and the predicted height before therapy (mean, 6.5 cm) correlated positively with the bone age advance (P < 0.01), negatively with the predicted height (P < 0.05), and positively with the difference between the target and predicted heights (P < 0.001) before therapy. In group 2, the adult height (162 +/- 1.4 cm) was similar to the predicted height at the initial evaluation (162.5 +/- 1.4 cm). Adult heights correlated with target height in group 1 and with predicted height at the initial evaluation in group 2. In conclusion, some girls with true precocious puberty and poor adult height prediction who are treated with GnRH analog achieve an adult height more comparable to their target height. However, the lack of effect on height in girls with predicted height at the onset of therapy similar to their target height and preservation of the growth potential in the slow evolutive forms suggest that these forms might not require immediate therapy. Careful follow-up before therapy may be a better way of evaluating their natural course.

This article has been cited by other articles:

				A. Ben-Haroush, H. Goldberg-Stern, M. Phillip, and L. de Vries GnRH agonist treatment in girls with precocious puberty does not compromise post-pubertal uterine size Hum. Reprod., March 1, 2007; 22(3): 895 - 900. [Abstract] [Full Text] [PDF]

				L. de Vries, G. Horev, M. Schwartz, and M. Phillip Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur. J. Endocrinol., June 1, 2006; 154(6): 891 - 898. [Abstract] [Full Text] [PDF]

				L. de Vries and M. Phillip Children Referred for Signs of Early Puberty Warrant Endocrine Evaluation and Follow-Up J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 593 - 593. [Full Text] [PDF]

				J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain Precocious puberty and statural growth Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147. [Abstract] [Full Text] [PDF]

				J. A. Yanovski, S. R. Rose, G. Municchi, O. H. Pescovitz, S. C. Hill, F. G. Cassorla, and G. B. Cutler Jr. Treatment with a Luteinizing Hormone-Releasing Hormone Agonist in Adolescents with Short Stature N. Engl. J. Med., March 6, 2003; 348(10): 908 - 917. [Abstract] [Full Text] [PDF]

				Long-Term Outcome after Depot Gonadotropin-Releasing Hormone Agonist Treatment of Central Precocious Puberty: Final Height, Body Proportions, Body Composition, Bone Mineral Density, and Reproductive Function J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4583 - 4590. [Abstract] [Full Text]

				C. Bouvattier, J. Coste, D. Rodrigue, C. Teinturier, J. C. Carel, J. L. Chaussain, and P. F. Bougneres Lack of Effect of GnRH Agonists on Final Height in Girls with Advanced Puberty: A Randomized Long-Term Pilot Study J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3575 - 3578. [Abstract] [Full Text] [PDF]

				P. B. Kaplowitz, S. E. Oberfield, and the Drug and Therapeutics and Executive Committees Reexamination of the Age Limit for Defining When Puberty Is Precocious in Girls in the United States: Implications for Evaluation and Treatment Pediatrics, October 1, 1999; 104(4): 936 - 941. [Abstract] [Full Text]

				A. Cassio, E. Cacciari, A. Balsamo, M. Bal, and D. Tassinari Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years Arch. Dis. Child., October 1, 1999; 81(4): 329 - 332. [Abstract] [Full Text]

				E. C. Walvoord and O. H. Pescovitz Combined Use of Growth Hormone and Gonadotropin-releasing Hormone Analogues in Precocious Puberty: Theoretic and Practical Considerations Pediatrics, October 1, 1999; 104(4): 1010 - 1014. [Abstract] [Full Text]

				J.-C. Carel, M. Roger, S. Ispas, F. Tondu, N. Lahlou, J. Blumberg, and J.-L. Chaussain Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1973 - 1978. [Abstract] [Full Text]

				A. M. Pasquino, I. Pucarelli, M. Segni, M. Matrunola, and F. Cerrone Adult Height in Girls with Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogues and Growth Hormone J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 449 - 452. [Abstract] [Full Text]

				S. L. S. Drop, W. J. de Waal, and S. M. P. F. de Muinck Keizer-Schrama Sex Steroid Treatment of Constitutionally Tall Stature Endocr. Rev., October 1, 1998; 19(5): 540 - 558. [Abstract] [Full Text]

				W F Paterson, E McNeill, S Reid, A S Hollman, and M D C Donaldson Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty Arch. Dis. Child., October 1, 1998; 79(4): 323 - 327. [Abstract] [Full Text]

				F. Cassorla, V. Mericq, M. Eggers, A. Avila, C. Garcia, A. Fuentes, S. R. Rose, and G. B. Cutler Jr. Effects of Luteinizing Hormone-Releasing Hormone Analog-Induced Pubertal Delay in Growth Hormone (GH)-Deficient Children Treated with GH: Preliminary Results J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3989 - 3992. [Abstract] [Full Text] [PDF]

				L. Adan, J. C. Souberbielle, J. M. Zucker, A. Pierre-Kahn, C. Kalifa, and R. Brauner Adult Height in 24 Patients Treated for Growth Hormone Deficiency and Early Puberty J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 229 - 233. [Abstract] [Full Text] [PDF]